There are several pharmacotherapies currently in development that show promise for improving outcomes in ET, such as T-type calcium channel modulators, CB-1 agonists, and GABA A receptor-positive allosteric modulators (37). The gene discussed is CNR1; the disease is essential thrombocythemia.